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To determine late patient outcome and homograft durability, we reviewed 326 patients 
who received aortic (n = 230) or pulmonary (n = 118) cryopreserved homografts for 
right ventricular outflow reconstruction between January 1985 and October 1993. 
Patient survival, including operative mortality, 5 years after the operation was similar 
between the two groups (pulmonary homograft 86%, aortic homograft 80%; p = not 
significant by log-rank test). However, 5-year freedom f~om homograft failure was 
significantly better for pulmonary homografts (94% versus 70%, p < 0.01 by log-rank 
test). Late calcification was evaluated by chest roentgenography and echocardiography. 
Overall, 20% of aortic homografts became moderately or severely calcified compared 
with 4% of pulmonary homografts (p < 0.01). Twenty-six percent of aortic homografts 
in children 4 years old or younger had moderate or severe obstruction associated with 
calcification, whereas only 11% of aortic homografts in patients over 4 years of age had 
calcißc obstruction (p < 0.01). No late deaths among patients receiving pulmonary 
homografts were related to graft failure; two late deaths in the aortic homograft group 
were homografl related. Risk factors for patient mortality and homograft failure 
(defined as either need for homograft replacement because of homograft ailure or as 
homograft-related death) were identified by the Cox multivariate analysis. Aortic type of 
homograft was a significant risk factor for homograft ailure (p < 0.0001), but type of 
homograft was not correlated with patient mortality. Age 4 years or younger was a 
significant risk factor for both mortality (p < 0.01) and homograft ailure (p = 0.03) in 
aortic homograft recipients but not in pulmonary homograft recipients. These results 
indicate that both aortic and pulmonary homografts provided excellent intermediate- 
term patient survival after ight ventricular outflow tract reconstruction, but pulmonary 
homografts are more durable than aortic homografts with less calcification and 
obstruction, especially among chfldren 4years old or younger. (J THORAC CARDIOVASC 
SURG 1995;109:509-18) 
Ko Bando, MD, a Gordon K. Danielson, MD, a Hartzell V. Schaft, MD, a 
Douglas D. Mair, MD, b Paul R. Julsrud, MD, c and Francisco J. Puga, MD, a 
Rochester, Minn. 
U se of an extracardiac conduit between the right 
ventricle and the pulmonary arteries has made 
possible the routine repair of pulmonary atresia, 1'z 
complex tetralogy of Fallot, 3 truncus arteriosus, 4 
transposition of the great arteries with ventricular 
septal defect and pulmonary stenosis, 5 and other 
complex forms of congenital heart disease. TM At- 
though techniques of reconstruction of the right 
ventricular outflow tract (RVOT) have been refined 
during the past 30 years, the search continues for an 
ideal conduit o establish right ventricle-pulmonary 
artery continuity. 12' 13 
Homografts are among the many varieties of 
prosthetic materials that have been used for RVOT 
reconstruction. At our institution, aortic valve ho- 
mografts were first used in September 1967. Late 
calcification and obstruction occurred in many pa- 
tients in our series and elsewhere; these c0mplica- 
tions appeared to be due in part to early methods of 
sterilization and preservation. 14-17 Recent promising 
results with fresh aortic homografts terilized with 
antibiotics and preserved with freezing have r sulted 
in a resurgence of use of homografts. TM 
Pulmonary homografts have a thinner wall than 
aortic homografts and may be less susceptible to 
calcification. However, few comparative data are avail- 
able on aortic versus pulmonary homografts. 19' 20 Ac- 
cordingly, we reviewed the results of cryopreserved 
aortic versus pulmonary homografts for reconstruction 
of the RVOT to determine risk factors for patient 
mortality and homograft failure. 
Patients and methods 
Between January 1, 1985, and October 30, 1993, 326 
consecutive patients received cryopreserved aortic (n = 
230) or pulmonary (n = 118) homografts for RVOT 
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Table I. Clinical data on 326 patients 
Initial homografl 
implantation 
Aortic Pulmonary 
Number 212 114 
Age 
Range 10 days-61 yr 3 days-48 yr 
Mean 11.4 yr 14.4 yr 
Median 9 yr 12 yr 
<4 yr 52 (24%) 22 (19%) 
Sex (male/female) 112/100 62/52 
Primary diagnosis 
Complex tetralogy of Fallot/ 117 (55%) 75 (66%) 
pulmonary atresia with VSD 
Truncus arteriosus 32 (15%) 10 (9%) 
Transposition of great arteries 32 (15%) 9 (8%) 
Double-outlet right ventricle 26 (12%) 9 (8%) 
Others 5 (2%) 11 (10%) 
Prior palliative procedures 112 (53%) 58 (51%) 
VSD, Ventricular septal defect. 
Table I I I .  Homografl anastomosis augrnentation 
techniques 
Aortic Pulmonary 
Procedure homograft homograft 
Proximal anastomosis 
Hemashield graft patch 61 14 
Bovine pericardium 51 25 
Autologous pericardium 13 12 
Remaining homograft 9 5 
Previous graft 5 3 
Other prosthetic material 5 7 
None or unknown* 86 52 
Distal anastomosis 
Hemashield graft patch 9 5 
Remaining homograft 7 0 
Bovine pericardium 7 1 
Autologous pericardium 6 5 
Previous graft 3 3 
Other prosthetic material 12 8 
None 186 96 
*Includes aortic homografts in which the anterior leaflet of the mitral valve 
was used. 
Table II. Primary indication for homografl 
implantation afier previous RVOT reconstruction 
Aortic Pulmonary 
Indication homograft homografl 
Failure of prosthetic valved conduit 60 28 
Failure of aortic homograft 17 3 
Failure of pulmonary homograft 3 4 
Pulmonary insutficiency 20 20 
Other 23 12 
Total 123 67 
reconstruction at the Mayo Clinic. Postoperative patient 
status was determined by evaluation of the patient or by 
letters from referring physicians. If recent (<6 months) 
follow-up had not been accomplished, the patients were 
contacted directly by telephone or letter during the 
months of January, February, and March 1994. Late 
homograft status was evaluated by one or more of the 
following: echocardiography, chest roentgenography, or 
cardiac atheterization. Clinical data are shown in Table I. 
One hundred twenty-one patients had received a nonho- 
mograft extracardiac conduit during a prior cardiac repair. 
Primary indications for 190 homograft implantations after 
prior RVOT reconstruction are shown in Table II. 
Most of the patients in whom a previous conduit had 
been placed underwent successful resternotomy and can- 
nulation of the ascending aorta. In some patients, partic- 
ularly those with prosthetic onduits that had eroded into 
the sternum or calcified homografts that lay beneath the 
sternum, the femoral artery and vein were cannulated 
before or during sternotomy. The operation was done 
with the use of standard cardiopulmonary b pass. In some 
patients who did not require associated intracardiac pro- 
cedures, the patient was cooled to 32 ° to 34 ° C, an aortic 
tack vent was placed, the heart was kept beating, and 
conduit replacement was done without crossclamping the 
aorta. In other patients and in those requiring an associ- 
ated intracardiac procedure, moderate hypothermia (20 ° 
to 28 ° C), aortic crossclamping, and myocardial protection 
with cold blood or crystalloid potassium cardioplegic 
solution were used. Exposure for the distal anastomosis 
was often facilitated with short periods of low flow (0.5 
L/min per square meter) or, rarely, circulatory arrest. 
Cryopreserved homografts were obtained from Cryo- 
Life Inc., Marietta, Georgia, Red Cross Transplantation 
Services, St. Paul, Minnesota, and United Cryo Institute, 
Chicago, Illinois. The techniques for preparation of cryo- 
preserved homografts and storage in liquid nitrogen have 
been described previously. 21' 22 Choice of conduit size was 
based on the patient size, pulmonary artery size, antici- 
pated somatic growth, and physical limitations of the 
sternum and mediastinal structures (Appendix 1). Except 
in some infants under i year of age, an effort was made to 
insert a homograft larger than the size predicted from 
tables of normal pulmonary valve sizes. 23' 24 Homografts 
were thawed and trimmed in standard fashion after 
intraoperative assessment of the anatomy. The distal 
anastomoses were performed first; the distal ends of the 
homografts were tailored to provide a maximal size of 
anastomosis and, where applicable, to enlarge proximal 
right and left pulmonary artery stenoses. A bifurcated 
reconstruction with a pulmonary homograft was used in 
27 patients. In some patients, other prosthetic material 
was used to extend the homograft, enlarge the pulmonary 
arteries, or provide continuity between the pulmonary 
arteries (Table III). Proximal anastomoses were made to 
vertical right ventriculotomies directed toward the site of 
the distal anastomosis, aspermitted by the coronary artery 
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anatomy. The anterior leaflet of the mitral valve, often 
extended with other material, was usually used in the 
proximal anastomoses of the aortic homografts. Most of 
the pulmonary homografts required prosthetic extension 
(Table III). Whenever possible, the conduits were posi- 
tioned away from the sternum to avoid compression. 
Selection of the homograft type was not random; sur- 
geon preference was the primary selection factor. In 
general, aortic homografts were used for patients who 
were expected to have pulmonary hypertension after the 
operation, and the majority of infants with truncus arte- 
riosus received aortic homografts. Pulmonary homografts 
were often used for patients requiring an anastomosis to
branch pulmonary arteries, or when augmentation f the 
pulmonary arteries was required. Pulmonary homografts 
were more frequently used for complex tetralogy of Fallot 
and for pulmonary atresia with ventricular septal defect 
and pulmonary stenosis. Because of the Scarcity of aortic 
homografts, pulmonary homografts were often implanted 
when the appropriate size of aortic homograft was not 
available, especially in the larger sizes. No attempt was 
made to achieve ABO blood type compatibility before 
June 1991; since then, ABO blood type compatible ho- 
mografts were implanted whenever possible. 
Early mortality was defined as death within 30 days. 
Data were entered into a computerized atabase and 
analyzed with Statistica software, Statsoft, Inc. Tulsa, 
Oklahorna. The cumulative survival estimates of patients 
and homografts were made by the actuarial (life-table) 
method and the 95% confidence intervals for the esti- 
mates were determined by the Greenwood formula. 2» 
Homograft failure was defined as the need for homograft 
replacement because of homograft failure or as death 
related to failure of the homograft. Homograft ailure was 
defined as conduit stenosis with or without calcification 
severe enough to warrant homograft replacement and 
conduit valve insufficiency severe enough to warrant ho- 
mograft replacement. Conduit compression between the 
heart and the sternum, proximal or distal homograft 
anastomotic stenosis, and development of a false aneu- 
rysm at the proximal or distal anastomosis were not 
considered homograft ailures. The Cox proportional haz- 
ard model was used to identify the independent contribu- 
tion of potential risk factors for patient mortality in the 
total cohort of 326 patients. The Cox model was also used 
to identify the independent risk factors for homograft 
failure in the entire group of 348 implanted homografts, as 
weil as in the subgroups with aortic (n = 230) and 
pulmonary (n = 118) homografts. The variables entered 
into the risk factor analysis are summarized in Table IV. 
The selection of independent variables in the models was 
a forward stepwise method with a critical p value for 
variable inclusion and exclusion of 0.15. Ap  value of less 
than 0.05 was considered significant. 
Results 
There were 22 early (6%) deaths related to the 
initial homograft implantation. Early rnortality for 
reoperation for conduit replacement was lower (6/ 
171, 3.5%) than early mortality for patients in whom 
homografts were implanted during the initial car- 
Table IV. Potential risk factors for patient mortality 
and homograft ailure 
Preoperative risk factors 
Age 
Sex 
Date of procedure 
Blood ABO patient - homograft mismatch 
Ratio of homograft size to body weight 
Cardiac diagnosis 
Previous paUiative procedure 
Previous repair or conduit 
Mean pulmonary artery pressure -> 45 mm Hg 
Operative risk factors 
Surgeon 
Technique of homograft extension 
Type of homograft 
Postrepair mean pulmonary artery pressure -> 45 mm Hg 
Postrepair right ventricular/left ventricular pressure ratio 
Table V. Primary cause of early death 
lnitial homograft recipients 
Cause 
Aortic Pulmonary 
hornograft homograft 
(n = 212) (n = H4) 
Acute ventricular failure 6 4 
Multisystem organ failure 3 0 
Pulmonary hypertensive crisis 2 1 
Neurologic deficit 2 1 
Sepsis 1 0 
Arrhythmia 1 0 
Myocardial infarction 1 0 
Total deaths 16 (7.5%) 6 (5.3%) 
diac repair (16/155, 10.3%). Early mortality was 
similar in patients who received aortic homografts 
and in those who received pulmonary homografts 
(16/212, 7.5%, versus 6/114, 5.3%). Primary causes 
of early death are shown in Table V. 
One patient in the aortic homograft group was 
lost to follow-up. Follow-up in the remaining pa- 
tients ranged from 6 months to 8.8 years with a 
mean of 2.7 years for aortic homografts and 3.2 
years for pulmonary homografts. There were 24 
(7.4%) late deaths. Sixteen of the 212 (7.5%) initial 
recipients of aortic homografts died late; two of the 
deaths were homograft related (one death at reop- 
eration and one death from an arrhythmia ssoci- 
ated with a high RVOT gradient) (Table VI). Eight 
late deaths (7.0%) were observed in the initial 114 
recipients of pulmonary homografts, but none were 
considered to be homograft related (Table VI). 
Overall survival, including early deaths, was 87% 
at 3 years after the operation and 83% at 5 years. 
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Table VI. Primary cause of late mortality 
Cause 
Initial homografl 
recipients 
Aortic Pulmonary 
homografi homografl 
(n = 212) (n = 114) 
Arrhythmia 6 3 
Heart failure 2 0 
Sepsis 2 1 
Multisystem organ failure 2 2 
Reoperation 1 1 
Pneurnonia 1 1 
Others 2 0 
Total deaths 16 (7.5%) 8 (7.0%) 
Survival was similar for patients with aortic and 
pulmonary homografls (5-year survival 80% and 
86%, respectively) (Fig. 1). Survival in children 4 
years of age or younger with aortic homografts was 
significantly less than in older patients with aortic 
homografts (p < 0.01) (Fig. 2, A), bnt age did not 
influence survival of patients receiving pulmonary 
homografts (Fig. 2, C). Five-year survival of patients 
receiving homografts at the time of initial cardiac 
repair (78%) was significantly less than survival of 
patients receiving homografts after previous repair 
(87%) (p = 0.01 by the log-rank test). However, this 
difference was due entirely to early mortality, be- 
cause later survival was similar in both groups. 
In the multivariate analysis of overall patient 
survival, homografl type was entered as a variable. 
Multivariate analysis was also applied separately to 
the patients who received aortic and pulmonary 
homografts. Overall patient survival was adversely 
affected by age of 4 years or younger at operation, 
initial repair with homograft, and smaller homograft 
size/body weight ratio (Table VII, A). These same 
factors were predictive of late death in the subgroup 
of patients receiving aortic homografts, but only 
smaller homograft size relative to body weight was 
predictive of late death in patients receiving pulmo- 
nary homografts. 
Late cardiac atheterization was performed in 40 
of 212 aortic homograft recipients and 23 of 114 
pulmonary homograft recipients. Follow-up data 
from one or more of the following, echocardiogram, 
chest x-ray film, or cardiac catheterization, were 
available for 197 aortic homografts and 104 pulmo- 
nary homografts. Moderate or severe graft calcifica- 
tion was identified in 20% of aortic homografts and 
4% of pulmonary homografts (Fig. 3). 
Twenty-three percent (53/230) of aortic ho- 
mografts became moderately or severely stenotic. 
Twenty-seven aortic homografts required reopera- 
tion because of stenosis; in 20 of these, obstruction 
was associated with calcification of the homograft 
(Table VIII). Two pulmonary homografts necessi- 
tated reoperation because of stenosis (both without 
calcification) and three pulmonary homografts ne- 
cessitated reoperation because of homograft valve 
insufficiency. Reoperation for indications other than 
homograft failure are also listed in Table VIII. 
Three of the 75 patients who received Hemashield 
graft patches (Meadox Medicals, Inc., Oakland, 
N.J.) for augmentation f the proximal anastomosis 
required reoperation for anastomotic stenosis. 
Twenty-six percent (14/53) of aortic homografts 
implanted in patients 4 years of age or younger 
became moderately or severely obstructed with cal- 
cification, whereas only 11% (20/177) of aortic ho- 
mografts implanted in patients older than 4 years 
became obstructed with calcificafion (p < 0.01). 
Only 4% (5/118) of pulmonary homografts became 
moderately stenotic with calcification; all but one 
had been implanted in patients older than 4 years. 
Thirty-two reoperations were required for con- 
duit failure in 28 patients. Twenty-five patients had 
one reoperation, two had two reoperations, and one 
patient had three reoperations for conduit failure. 
Twenty-seven reoperations were for aortic ho- 
mograft failure and five were for pulmonary ho- 
mograft failure (p = 0.02) (see Table VIII). How- 
ever, if false aneurysms, all three of which occurred 
in the pulmonary homografts, are included in the 
definition of homograft ailure, the differences were 
not significant (p = 0.14). If all causes of reopera- 
tion are considered, the reoperation rate for pulmo- 
nary compared with aortic homografts was also not 
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Table VII. Results of multivariate analysis of risk factors for late patient mortality and homograft ailure 
Homo~aß 
Risk factor Overall Aortic Pulmonary 
A. Pat ient  mortal i ty 
Age ~4 years old 
Initial repair with homograft 
Smaller homograft size/body weight 
B. Homograft failure 
Aortic homograft 
Age ~4 years old 
Cardiac diagnosis (TA, TGA, DORV, and others) 
p < 0.001 p < 0.001 NS 
p < 0.01 p < 0.01 NS 
p < 0.001 p < 0.001 p = 0.02 
p < 0.0001 - -  - -  
p = 0.01 p = 0.03 NS 
p = 0.03 p = 0.04 NS 
TA, Truncus arteriosus; TGA, transposition of great arteries; DORV, double-outlet right ventricle; NS, not significant. 
significant (p = 0.25). Replacement conduits were 
as follows: aortic homograft (n = 21), pulmonary 
homograft (n = 4), Hancock conduit (n = 4), 
porcine valve with pericardial roof reconstruction (
= 2), and nonvalved pericardial roof reconstruction 
(n = 1). 
Actuarial freedom from failure of pulmonary 
homografts was significantly higher than that of 
aortic homografts (5-year freedom from failure 94% 
versus 70%, Fig. 4). Freedom from failure of aortic 
homografts inpatients 4years of age or younger was 
significantly ower than for older patients (Fig. 2, B), 
but age had little effect on freedom from failure for 
pulmonary homografts (Fig. 2, D). 
By Cox multivariate analysis, type of homograft 
(aortic versus pulmonary) was the strongest predic- 
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Table VIII. Indication for reoperation 
Indication 
Homo~afi 
Aortic Pulmonary 
Homograft failure 27 
Homograft stenosis 27 
With calcification 20 
Without calcification 7 
Homograft valve insufficiency 0 
Homograft compression 1 
False aneurysm, distal anastomosis 0 
False aneurysm, proximal anastomosis 0 
Stenosis proximal anastomosis 3 
Total 31 
5 
2 
3 
3 
2 
1 
0 
11 
tor of homografl ailure (Table VII, B). Age 4 years 
or younger and cardiac diagnosis group of truncus 
arteriosus, transposition of the great arteries, dou- 
ble-outlet right ventricle, and others were also pre- 
dictive of late homograft ailure for the entire group 
and for the aortic homograft group. The cardiac 
diagnosis group of tetralogy of Fallot and pulmo- 
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Fig. 5. A, Patient survival including early mortality for all 
homografts stratified according to diagnostic groups. B, 
Freedom from homograft ailure stratified according to 
diagnostic groups. Complex tetralogy of Fallot (TOF) and 
pulmonary atresia with ventricular septal defect (PA + 
VSD) represent one group and truncus arteriosus (TAL 
transposition f great arteries (TGA), dòuble-outlet right 
ventricle (DORV), and others represent the other group. 
Vertical bars enclose a95% confidence interval. NS, Not 
significant. 
nary atresia with ventricular septal defect had a 
higher freedom from homograft ailure (Fig. 5, B) 
(t, = 0.01).  
By multivariate analysis, preoperative pulmonary 
hypertension was not a significant risk factor for 
patient mortality, which was 18% in those with 
pulmonary hypertension and 11% in those without 
pulmonary hypertension (p = not significant). Pul- 
monary hypertension was also not a significant risk 
factor for homograft ailure, which occurred in 8% 
of patients with pulmonary hypertension compared 
with 11% of patients without pulmonary hyperten- 
sion (p = not significant). There were no significant 
differences in preoperative systolic pulmonary pres- 
sure between onsurvivors (41.4 + 21.4 mm Hg) 
and survivors (37.8 + 19.4 mm Hg) or between 
patients with homograft failure (36.3 _+ 19.8 mm 
Hg) and those without homograft failure (38.6 _+ 
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19.7 mm Hg). Homograft survival was not signifi- 
cantly influenced by the type of material used for 
augmentation of the homograft anastomoses, date 
of procedure, ABO blood type matching of the 
homograft and patient, or other factors mentioned 
in Table IV. 
The percentages of late survivors who were in 
New York Heart Association class I or II were 94% 
(170/180) in the aortic homograft group and 92% 
(92/100) in the pulmonary homograft group. 
Discussion 
The use of homografts for RVOT reconstruction 
was first reported for pulmonary atresia in 1966, 2for 
truncus arteriosus in 1968, 4and for transposition of 
the great arteries with ventricular septal defect and 
pulmonary stenosis in 19695; by the 1970s, ho- 
mografts had become widely used for RVOT recon- 
struction in many types of complex congenital heart 
disease. 6-11 However, because of problems with late 
calcification and obstruction, many centers discon- 
tinued the use of homografts and changed to pros- 
thetic grafts with porcine valves. 26' 27 Subsequent 
experience with those conduits howed late obstruc- 
tion by calcification of the porcine valve and by peel 
formation. 2s Recent reports of encouraging late 
results with antibiotic-sterilized homografts 29 and 
especially with fresh aortic homografts terilized 
with antibiotics and preserved with freezing 18 have 
resulted in a resurgence of interest in homografts. 
Our experience with sterile, fresh cryopreserved 
homografts began in 1985. 
This study and others 19 have demonstrated xcel- 
lent patient survival after RVOT reconstruction 
with cryopreserved homografts and low risk of mor- 
tality for reoperation for conduit replacement. 3° 
However, aortic homograft failure in this series was 
more than expected. Other investigators have also 
expressed concerns about he durability of cryopre- 
served aortic homografts. 19In addition, both calci- 
fication and conduit stenosis were greater in the 
aortic homografts in this series. A higher rate of 
calcification in aortic homografts compared with 
pulmonary homografts may be related to a greater 
content of elastic tissue and a greater amount of 
total calcium in the wall of the aortic homograft. 31
Accelerated egeneration of aortic homografts in 
young patients has been observed by others 32 and 
was a statistically significant risk factor in this series. 
Accelerated egeneration may be related to a host 
immunologic response, although this theory remains 
unproved. 33 
A few of our homografts failed without calcifica- 
tion. The homografts were contracted and edema- 
tous, and thrombus was sometimes een in the 
retracted cusps. Some of these homograft failures 
occurred within 2 years of implantation and had the 
appearance of an immunologic response. ABO in- 
compatibility and immunologic response as risk 
factors for homograft durability have been debated 
extensively. 33-35 In this series, we could not demon- 
strate a relationship of ABO incompatibility with 
homograft survival, but the number of patients may 
be too small to demonstrate a difference. The role of 
viable cells in cryopreserved homografts i another 
issue of uncertain significance, but this may actually 
be detrimental compared with survival of refrigera- 
tor-stored antibiotic-preserved homografts, inwhich 
most cells, especially endothelial cells, are no longer 
viable after 48 hours. 
Although the type of material used for augmen- 
tation of the homograft anastomoses was not a 
statistically significant risk factor, there were three 
instances of proximal stenosis resulting from failure 
of a Hemashield patch; this material has also been 
reported by others to contribute to anastomotic 
stenosis.36, 37
Small size of the homograft compared with body 
weight was a significant risk factor for patient mor- 
tality and also for late overall homograft and aortic 
homograft failure in this series. Other reports have 
not found the size of the homograft o be a risk 
factor for late failure. 38' 39 
In summary, for RVOT reconstruction, pulmo- 
nary homografts were more durable than aortic 
homografts, especially among young children. Small 
homograft size relative to patient body weight and 
the diagnostic group of truncus arteriosus, transpo- 
sition of the great arteries, double-outlet right ven- 
tricle, and others were significant risk factors for 
subsequent homograft failure. Pulmonary homo- 
grafts appear to be the preferred conduits for most 
cases of RVOT reconstruction, especially in patients 
4 years of age or younger. 
We gratefully acknowledge the excellent assistance of 
Kunikazu Hisamochi, MD, Terumasa Morita, MD, and 
Betty J. Anderson, RN, who helped with patient review 
and data entry in this study. 
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Discuss ion 
Dr. David R. Clarke (Denver, Colo.). The data pre- 
sented parallel our experien¢e in Denver for homograft 
reconstmction of the RVOT. We have a mean of 4 years 
of clinieal follow-up of 200 patients; 29 re¢eived aorti¢ 
homografts and 171 received pulmonary homografts to 
re¢onstruct the RVOT over a ¢omparable time interval. In 
the Denver series, conduit failure that neeessitated re- 
placement was more prevalent with aortic homografts 
(24% failure) than with pulmonary homografts (4.7% 
failure). Reeipient age at implantation also significantly 
affected failure rate. 
My first question relates to diagnosis and patient age at 
the time of homograft implantation. In our experience 
that is similar to yours, 47% of homografts that required 
replacement had been implanted in children with truncus 
arteriosus. Because this anomaly usually mandates surgi- 
cal repair at an early age in your series, can you clearly 
separate diagnosis and age at operation as independent 
risk factors, and can you comment on this phenomenon 
please? 
Dr. Bando. Diagnosis and age at operation are interre- 
lated in part by the associations you mentioned. However, 
on multivariate analysis of our data, both age and the 
diagnostic group of truncus, double-outlet right ventricle, 
and transposition of the great arteries were found to be 
independent risk factors for homograft failure. 
Dr. Clarke. Our current policy regarding implantation 
of aortic valve homografts in the RVOT differs from yours 
because you intentionally selected aortic conduits for 
specific patients. The majority of Denver's aortic ho- 
mografts represent our early experience; since 1988 we 
have implanted aortic homografts only when the appro- 
priate pulmonary homograft is unavailable. After having 
evaluated and reported your current series, will you 
reassess your future use of aortic homografts in the 
RVOT? 
Dr. Bando. This is the first analysis of out late homograft 
experience. We have confirmed that the failure rate of the 
aortic homograft is higher than that of the pulmonary 
homograft, so we now prefer to implant pulmonaIy ho- 
mografts whenever feasible. 
Dr. Clarke. In your paper you cited three organizations 
as sources for the tissue that was implanted, lnasmuch as 
minor variations may exist in the preservation processes 
among these organizations and these variations might 
account for sorne differences in viability that could be 
important, did you evaluate tissue source as a risk factor? 
Do you have any subjective feeling about differences that 
exist there? 
Dr. Bando. Tissue source was not evaluated as a risk 
factor. 
Dr. Clarke. Allograft degeneration i  younger patients 
has been a problem in both our series. Denver data reveal 
a higher prevalence of allograft fibrocalcification and 
regurgitation i  young patients. Of the 15 patients who 
underwent reoperation to replace an aortic or pulmonary 
allograft in out series, 13 (87%) were less than 4 years of 
age at the initial allograft operation. We have been unable 
to pinpoint a mechanism for early conduit failure, but like 
you we have considered the possibility of an immunologic 
reaction. My question is a monumental one and concerns 
the immune response that might occur in younger chil- 
dren. From the data you have so thoroughly researched, 
can you and your colleagues hed any light on the 
presence and/or nature of this phenomenon? 
Dr. Bando. A few of our homografts failed very early, 
without calcification. Edema and thrombus were found 
around the cusp area. We believe that in those particular 
cases the patients clearly had rejection. The role of the 
immune response in graft failure is controversial. How- 
ever, in at least some cases, it appears that viable cells in 
the cryopreserved homograft may be detrimental. We 
have not used any form of immunosuppression. 
Dr. Ronald Elkins (Oklahoma City, Okla.). I have two 
questions: What would you recommend for the older 
patient with known pulmonary hypertension requiring 
conduit reconstruction of the RVOT? It is fairly well 
known that the pulmonary homograft will fall fairly early 
from pulmonary insutficiency in this setting. 
Dr. Bando. For initial operation in a patient with 
pulmonary hypertension, we prefer an aortic homograft or 
a porcine-valved Dacron conduit. For reoperation, we 
prefer an autologous tissue reconstruction employing a 
pericardial roof patch over a porcine valve. 
Dr. Elkins. My second question relates to our experi- 
ence prirnarily with the pulmonary autograft procedure. 
We have approximately 170 patients now. Among thern 
were two patients in whom a discrete narrowing of the 
pulmonary homograft developed istal to the pulmonary 
valve within the first year after the operation. In talking to 
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other surgeons with similar experience across the country, 
we learned that most of them have had one or two similar 
cases. Have you seen similar lesions in those patients in 
whom reconstruction was done primarily for congenital 
lesions rather than for movement of the normal pulmo- 
nary valve from the RVOT? Do you have any thoughts as 
to the etiology of this other than perhaps an unusual 
rejection phenomenon? 
Dr. Bando. We are aware of stenosis of pulmonary 
homografts employed both in congenital lesions and as 
replacement of a native pulmonary valve in the autograft 
operation. We have no explanation for these occurrences 
but suspect early pulmonary homograft stenosis, espe- 
cially without calcification, is a rejection phenomenon. 
Dr. Edward Verrier (Seattle, Wash.). I have two rela- 
tively straightforward questions. A greater percentage of 
aortic conduits were used in patients with pulmonary 
hypertension. Although the numbers did not achieve 
significance, I am interested in the relationship, because 
clearly biomechanical factors and stress/strain relation- 
ships across the valve or conduit have been shown both 
experimentally and in the valve literature to potentiate 
the calcification issue. Could you further comment on the 
relationship between pulmonary hypertension and the 
early development of calcification in the aortic conduits? 
Dr. Bando. We specifically looked at that matter and 
compared survivors and nonsurvivors. Preoperative pul- 
monary artery pressure was not different. Furthermore, 
we found no significant difference between patients whose 
homografts failed and those whose homografts did not 
fail, so I have no good explanation for that. The only thing 
I can say is that from these data preoperative pulmonary 
hypertension did not appear to be a significant risk factor. 
Dr. Verrier. In explanted conduits, have you looked at 
the endothelium for the development of intimal hyperpla- 
sia or vascular adhesion molecules or procollagen expres- 
sion? Such factors may potentiate the proliferative ob- 
structive process that frequently is associated with the 
calcification. 
Dr. Bando. That is a very good point. We have not yet 
done special studies on the explanted homografts, o we 
cannot comment further regarding endothelial mecha- 
nisms for homograft failure. 
Dr. Davis Drinkwater (LosAngeles, Calif). We recently 
evaluated our experience in this area at the University of 
California at Los Angeles. Like you and the Toronto 
group, we found that the best long-term results may be 
achieved with a large-sized allograft in the orthotopic 
position. We did not, however, find a difference between 
the aortic and pulmonary homografts, as you did. Indeed, 
we found that the use of an oversized orthotopic xenograft 
in the form of a bioprosthetic valve had excellent longev- 
ity. I am wondering whether you can clarify several issues. 
You said that the extension material did not appear to be 
a factor. Was the material placed as a cireumferential 
extension, which was a commonly practiced technique in 
making right ventricle-pulmonary artery conrlections, or 
were they just pateh overlays? Early on, we also used this 
technique for extending the homograft away from the 
sternum, and we found that the circumferential configu- 
ration was at greater isk for future obstruction because of 
intimal proliferation. 
Dr. Bando. We use it as a patch overlay. 
Dr. Drinkwater. Was the difference in age groups 
between the aortic and the pulmonary homograft (I think 
it was 11 versus almost 15 years) a significant one in terms 
of the outcome data? Does this difference reflect a 
differing time period and, therefore, have bearing on the 
outcome data resulting from improved preservation and 
handling techniques in the more modern era? 
Dr. Bande. I do not think so. We looked at both the 
anastomosis material and the anastomosis technique, and 
there was no difference. 
Dr. EI-Gamel (Manchester, United Kingdom). Have you 
looked at the donor age of the aortic homografts and 
correlated thät with the degree of calcification? Do you 
think that is possibly a risk factor? 
Dr. Bando. We tried to obtain the donor age but were 
successful in only about 80%. Thus we could not include 
the data in the multivariate analysis. 
Appendix 1. Patient weight and homografi size 
Homo~aß 
Aortic Pulmonary 
Weight at operation (kg) 
Range 2.3-91.2 3.0-131.0 
Mean 33.7 40.9 
Median 28.0 42.6 
Conduit anulus diameter (mm) 
Range 7-28.5 15-32 
Mean 20.5 23.4 
Median 21.0 23.0 
